Advertisement

Topics

Familial Hypercholesterolemia Type II Hyperlipoproteinemia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

10:55 EDT 10 Aug 2017 | BioPortfolio Reports

DelveInsight's, Familial Hypercholesterolemia Type II Hyperlipoproteinemia Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Familial Hypercholesterolemia Type II Hyperlipoproteinemia. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Familial Hypercholesterolemia Type II Hyperlipoproteinemia. This report provides information on the therapeutic development for Familial Hypercholesterolemia Type II Hyperlipoproteinemia, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Sanofi;Merck Co. Inc.;Aegerion Pharmaceuticals Inc.;Regeneron Pharmaceuticals Inc.;Medpace Holdings Inc.;Ionis Pharmaceuticals Inc.;AstraZeneca Plc;Pfizer Inc.;Amgen Inc.;Dr. Reddy's Laboratories Limited
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Pipeline Drugs
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Pipeline Assessment
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Pipeline Analysis
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Drugs under Development
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Discovery drugs
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Preclinical drugs
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Phase I drugs
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Phase II drugs
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Phase III Pipeline Drugs Assessment
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Preregistration drugs
Familial Hypercholesterolemia Type II Hyperlipoproteinemia Molecules in pipeline

Original Article: Familial Hypercholesterolemia Type II Hyperlipoproteinemia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

NEXT ARTICLE

More From BioPortfolio on "Familial Hypercholesterolemia Type II Hyperlipoproteinemia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...